Life Sciences Tools and Services

PR 于 4 月 28 日盘后 (北京时间) 发布 FY2025 年报，实际营收 6.88 亿 CNY (预期 6.79 亿 CNY)，实际 EPS 0.24 CNY (预期 0.33 CNY)

PR 于 4 月 28 日盘后 (北京时间) 发布 FY2026 Q1 财报，实际营收 1.72 亿 CNY，EPS 0.17 CNY

PR 于 4 月 28 日盘后 (北京时间) 发布 FY2025 Q4 财报，实际营收 1.74 亿 CNY，实际 EPS -0.0035 CNY

PR FY2026 Q1 Earning Release on April 29 After-Market (BJT)

PR to Release FY2025 Earnings on April 29 After-Market (BJT), Forecast Revenue CNY 679 M, EPS CNY 0.33

PR released FY2025 9 Months earnings on October 29 After-Market (BJT), actual revenue CNY 514.4M, actual EPS CNY 0.2495

PR released FY2025 Q3 earnings on October 29 After-Market BJT, actual revenue CNY 161.66 M, actual EPS CNY 0.0695

PR to Release FY2025 Q3 Earnings on October 30 After-Market BJT

PR released FY2025 Q2 earnings on August 27 Pre-Market (BJT), actual revenue CNY 183.31 M, actual EPS CNY 0.09

PR released FY2025 Semi-Annual earnings on August 27 Pre-Market (BJT), actual revenue CNY 352.74 M, actual EPS CNY 0.18

PR to Release FY2025 Semi-Annual Earnings on August 28, 2025 (BJT)

Hongbo Pharmaceutical Announces 2025 H1 Earnings Forecast

Hongbo Pharmaceutical's Net Profit Forecast to Increase in H1 2025

Pacific Researcher Gives Buy Rating to Honbo Pharmaceutical

Huonbo Medicine Shareholder Suggests Increasing Media Communication Budget

Sunnyport Biopharmaceutical Co., Ltd. Shareholder Shenyang Funbang Completed 1.00% Share Reduction

Honeysuckle Pharma Stock Rises, Given a Buy Rating by Research Report

Pacific Researcher Issues Buy Rating Report on Hongbo Medicine

Hollybio Pharmaceutical Shareholder Plans to Reduce Holdings

Hóngbó Medical Announces 226.47% YOY Net Profit Growth in Q1 2025

301230

301333

000516

300404

688246

AI healthcare and AI pharmaceutical concepts are experiencing volatile adjustments, with PR falling over 18%, R&G Pharma down nearly 15%, and IMIC, BOJI CRO, GOODWILL, and Berry Genomics all dropping more than 5%

Wallstreetcn

R&G Pharma

IMIC

BOJI CRO

GOODWILL

PR: At this stage, the direct revenue from the company's DiOrion platform drug development services accounts for a small proportion of the company's overall operating income, which does not have a significant impact on the company's overall operating situation

PR released its third-quarter report for 2025, with operating revenue for the first three quarters amounting to 514 million yuan, a year-on-year increase of 31.43%. The net profit attributable to shareholders of the listed company was 34.7496 million yuan, a year-on-year increase of 127.96%. The net profit after deducting non-recurring gains and losses was 27.7095 million yuan, a year-on-year increase of 353.43%. The basic earnings per share were 0.2489 yuan

Zhitong

PR released its performance for the first three quarters, with a net profit attributable to the parent company of 34.7496 million yuan, an increase of 127.96%

PR announced that the company's consolidated net profit for the first three quarters of 2025 was 34.7496 million yuan. As of the board meeting date, the total share capital, excluding repurchased shares, was 138 million shares. The company plans to distribute a cash dividend of 1 yuan for every 10 shares to all shareholders based on the total share capital issued as of the equity registration date, excluding the number of repurchased shares, with an expected cash dividend distribution of 13.754 million yuan. This plan is subject to approval at the third extraordinary general meeting of shareholders in 2025

PR: It plans to distribute 13.754 million yuan in cash for the first three quarters of 2025

300347

03347

603456

301393

The innovative drug concept surged in the afternoon, with Nossan hitting the 20% limit up, followed by gains in PR, Tigermed, Jiuzhou Pharma, and Highfine

Tigermed

TIGERMED

Jiuzhou Pharma

Highfine

On September 25th, PR stated on the interactive platform that the company is a one-stop comprehensive service provider for new drug research and development and commercial production, with business involvement in numerous therapeutic areas, including the weight loss sector

PR: The company's business includes the weight loss sector

PR announced that in the first half of 2025, the operating revenue was 353 million yuan, a year-on-year increase of 32.73%. The net profit was 24.7614 million yuan, a year-on-year increase of 54.99%. The company plans to distribute a cash dividend of 0.7 yuan for every 10 shares to all shareholders based on the total share capital issued as of the equity registration date for the implementation of the profit distribution plan, excluding the number of repurchased shares, with no bonus shares and no capital increase from reserves

PR: In the first half of 2025, the net profit was 24.7614 million yuan, a year-on-year increase of 54.99%

688117

300012

300149

688553

The CRO concept surged sharply at the beginning of the session, with ChemPartner rising over 11%, HUIYU PHARMACEUTICAL, SNSW, CTI, and PR all rising over 5%

SNSW

ChemPartner

HUIYU PHARMACEUTICAL

According to the Zhitong Finance APP, PR announced that the share reduction plan of its shareholder Shenyang Fubang has been completed. Shenyang Fubang has cumulatively reduced its holdings in the company by 1.37 million shares through centralized bidding and block trading, with a reduction ratio of 1.00%

Shareholder of PR, Shenyang Fubang, has completed a reduction in holdings, with a total reduction of 1% of shares

301096

688222

301520

301509

The medical services sector has seen a short-term decline, with Kingchem dropping over 8%, followed by PR, Bio-S, HitGen, and AHWB

Bio-S

HitGen

AHWB

Kingchem

The medical services sector has seen a short-term decline, with Kingchem falling over 8%

PR(301230.SZ)